Washington University School of Medicine: Leukemia trials

The registry lists 38 Leukemia studies with Washington University School of Medicine as lead sponsor. 1 are open to participants now and 18 have results posted.

Early Phase 1 2Phase 1 24Phase 2 21No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Weight Gain in Pediatric Leukemia SurvivorsNot yet recruitingNCT07374315Not applicable
• Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)TerminatedNCT04582864Phase 2Results posted
• PROactive Evaluation of Function to Avoid CardioToxicityTerminatedNCT03862131Phase 2Results posted
• Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell TransplantationCompletedNCT03755414Phase 1Results posted
• Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid LeukemiaTerminatedNCT03063203Phase 2Results posted
• BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic LymphomaTerminatedNCT02763384Phase 2Results posted
• Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological MalignanciesCompletedNCT02639559Phase 2Results posted
• Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02416908Phase 1/2Results posted
• Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)TerminatedNCT01898793Phase 1/2Results posted
• Azacitidine in Patients Undergoing Matched Unrelated Stem Cell TransplantationTerminatedNCT01747499Phase 1/2Results posted
• Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT01687400Phase 2Results posted
• Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling DonorsCompletedNCT01158118Phase 2Results posted
• Azacitidine and Lenalidomide for Acute Myeloid LeukemiaCompletedNCT01016600Phase 1/2Results posted
• EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia LymphomaCompletedNCT01000285Phase 1/2Results posted
• Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid LeukemiaCompletedNCT00906945Phase 1/2Results posted
• LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)CompletedNCT00691938Phase 1/2Results posted
• Lenalidomide in Older Patients With Acute Myeloid Leukemia Without Chromosome 5q AbnormalitiesCompletedNCT00546897Phase 2Results posted
• AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid LeukemiaCompletedNCT00512252Phase 1/2Results posted
• Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological MalignanciesCompletedNCT00241358Phase 1/2Results posted
• Family-Based Behavioral Treatment for Childhood Survivors of Acute Lymphoblastic LeukemiaTerminatedNCT05410574Not applicable
• Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDSWithdrawnNCT04893915Phase 2
• Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AMLWithdrawnNCT04354025Phase 2
• CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid LeukemiaCompletedNCT02995655Phase 1
• Azacitidine in Haploidentical Donor Hematopoietic Cell TransplantationTerminatedNCT02750254Phase 1
• Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)WithdrawnNCT02564536Phase 1
• Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell TransplantationCompletedNCT02117115Early Phase 1
• Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02057770Phase 1
• Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell TransplantationCompletedNCT01700751Phase 1
• Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell TransplantCompletedNCT01390311Phase 1
• Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic LeukemiaCompletedNCT01331590Early Phase 1
• Carfilzomib in Patients With Relapsed Acute Myeloid or Acute Lymphoblastic LeukemiaCompletedNCT01137747Phase 1
• IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML)TerminatedNCT01027923Phase 1
• Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML)CompletedNCT01001143Phase 1
• Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post TransplantCompletedNCT00986804Phase 1
• Oral Clofarabine for Acute Myeloid LeukemiaCompletedNCT00727766Phase 1
• Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid LeukemiaCompletedNCT00671697Phase 1
• Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic LeukemiaCompletedNCT00008697Phase 1/2
• Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous TherapyTerminatedNCT00006220Phase 1/2